Genentech, Biogen Receive Complete Response From FDA For Rituxan
Genentech, a wholly-owned member of the Roche Group and Biogen Idec have received a complete response from the FDA for a supplemental Biologics License Application (sBLA) for Rituxan
US-based biotechnology company Superluminal Medicines has completed a $60m Series B financing round to support its research into therapies for rare genetic forms of obesity and hypothalamic obesity.